One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are ...

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 ...

Alphabet's AI drug development subsidiary Isomorphic Labs is aiming to initiate clinical trials for its AI-developed oncology drugs. In an interview with Fortune, Isomorphic Labs president Colin ...

Out to make a bigger difference, Alphabet’s Isomorphic Labs is exploring a much more useful application of AI. The Google ...

Google DeepMind's Isomorphic Labs is set to begin human trials of drugs designed by artificial intelligence, marking a ...

As Isomorphic Labs aims its artificial intelligence tools at drug ... that we can use AI to really transform and reimagine how we discover drugs,” said Isomorphic President Colin Murdoch.

Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence. ... with proven drug development expertise," said Colin Murdoch, President of Isomorphic Labs.

Isomorphic Labs sets up U.S. presence, ... “Our core thesis was, and is, that we can use AI to really transform and reimagine how we discover drugs,” said Isomorphic President Colin Murdoch.

Isomorphic Labs advances towards human clinical trials for AI-designed drugs, marking a pivotal moment in pharmaceutical ...

LONDON and BOSTON, June 17, 2025 /PRNewswire/ -- Isomorphic Labs, ... with proven drug development expertise," said Colin Murdoch, President of Isomorphic Labs.